Document Detail

Engineering cell platforms for myocardial regeneration.
MedLine Citation:
PMID:  21542780     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Various engineered 'cell-platforms' have been reported in recent years for the possible treatment of myocardial infarction (MI) and end-stage heart failure. These engineered platforms rely on two key factors: cells and/or biomaterial scaffolds for the regeneration of the infarcted heart tissue.
AREAS COVERED: Two major cell-platform approaches are described and broadly categorized as 'injectable cell platforms' and 'patch-based cell platforms'. The recent advancements in these cell-platforms in terms of their relative successes in-vivo as well as their clinical feasibility are summarized. Natural as well as synthetic scaffolds, with or without the cellular component, are compared with cell based therapy alone. This review focuses on achievements, as well as the gaps that are presently checking any progress towards producing clinically relevant panacea for myocardial regeneration.
EXPERT OPINION: Cardiac and induced pluripotent stem cells will probably be the focus of future research. The combined cell-biomaterial scaffold therapy is superior to cell therapy alone. Nevertheless, encouraging pre-clinical successes have limited translation into clinical practice due to limited cell survival post transplantation, inadequate construct thicknesses for human-sized hearts and the traditional use of 'flat (2D) tissue culture' techniques. The development of complementary dynamic 3D cultivation platforms will probably lead to improved outcomes and enable fast screening of various therapeutic approaches.
Udi Sarig; Marcelle Machluf
Publication Detail:
Type:  Journal Article; Review     Date:  2011-05-05
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  11     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-06-29     Completed Date:  2011-11-08     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1055-77     Citation Subset:  IM    
Technion-Israel Institute of Technology, The Laboratory of Cancer, Drug Delivery & Mammalian Cell Technology, Faculty of Biotechnology & Food Engineering, Haifa 32000, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiovascular Diseases / therapy*
Cell Transplantation*
Myocytes, Cardiac / cytology,  physiology*
Tissue Engineering*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  On total disc replacement.
Next Document:  Analysis of the bacterial community within carrot wash water.